logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
after Q4 2018
Akebia Therapeutics, Inc.
Data from phase II trial of Vadadustat (FO2RWARD)
Dialysis Patients with Anemia Related to Chronic Kidney Disease
after Q4 2018
Akebia Therapeutics, Inc.
Data from phase II trial of Vadadustat (FO2RWARD)
Dialysis Patients with Anemia Related to Chronic Kidney Disease
after Q4 2018
ObsEva SA
Initial efficacy results from phase 2a clinical trial of OBE022 (PROLONG)
Pre-term labor
after Q4 2018
VANDA PHARMACEUTICALS
Results from phase III trial of Tradipitant
Gastroparesis
after Q4 2018
VANDA PHARMACEUTICALS
Results from phase III study of HETLIOZ
Smith-Magenis Syndrome
after Q4 2018
BioXcel Therapeutics, Inc.
Data readout from Phase 2 PoC open label clinical trials for BXCL501 program
Acute Treatment of Agitation
after Q4 2018
Bellerophon Therapeutics LLC
Top-line data from full phase III INOvation-1 study of INOpulse
Pulmonary arterial hypertension
after Q4 2018
Bellerophon Therapeutics LLC
Top-line results from phase 2b study of INOpulse
Pulmonary hypertension with Interstitial Lung Disease (PH-ILD)
after Q4 2018
TYME TECHNOLOGIES, INC.
Initial results from first stage of Phase II clinical trial of SM-88
Metastatic pancreatic cancer
after Q4 2018
TYME TECHNOLOGIES, INC.
Additional data from ongoing Phase II clinical trial of SM-88
Prostate cancer
after Q4 2018
Eli Lilly And Co.
PFS data readout from ongoing Phase 3 study of CYRAMZA
EGFR-positive non-small cell lung cancer
after Q4 2018
TYME TECHNOLOGIES, INC.
Interim data from phase II trial of SM-88
metastatic pancreatic cancer
after Q4 2018
uniQure N.V.
Data from dose confirmation study of AMT-061
Hemophilia B
after Q4 2018
Regenxbio Inc
Topline data from RGX-314 Phase I clinical trial
wet age-related macular degeneration (wet AMD)
after Q4 2018
Regenxbio Inc
Topline data from RGX-501 Phase I/II clinical trial
Homozygous Familial Hypercholesterolemia (HoFH)
after Q4 2018
Nightstar Therapeutics plc
Initial data from dose escalation cohorts of Phase 1/2 Gene Therapy (NSR-RPGR) clinical trial
X-Linked Retinitis Pigmentosa (XLRP)
after Q4 2018
SteadyMed Ltd.
Resubmission of Trevyent NDA
Pulmonary Arterial Hypertension
after Q4 2018
Nymox Pharmaceutical Corporation
Submission of NDA for Fexapotide Triflutate
Benign prostatic hyperplasia
after Q4 2018
Ophthotech Corp.
Initial top-line data from phase 2a clinical trial of Zimura
Wet age-related macular degeneration
Sep 2018
Esperion Therapeutics
Top-line results from the pivotal Phase 3 Study 2 (1002-047) of bempedoic acid
ASCVD patients on maximally tolerated statin background therapy
after Q4 2018
Sarepta Therapeutics
60-day biopsy data from Phase 1/2a study of MYO-101
LGMD2E (beta-sarcoglycanopathy)
after Q4 2018
Xenetic Biosciences, Inc.
Interim data from phase II clinical study of XBIO-101 in conjunction with progestin therapy
Endometrial cancer
after Q4 2018
BeyondSpring Inc.
Topline Phase 2 data for Study 106 evaluating Plinabulin + TAC (Taxotere/Adriamycin/cyclophosphamide)
Chemotherapy-induced neutropenia (CIN)
after Q4 2018
BeyondSpring Inc.
Submission of NDA for Plinabulin
Chemotherapy-induced neutropenia (CIN)
01-Sep-2018 To 30-Nov-2018
Mirati Therapeutics, Inc.
Update from phase II study of Sitravatinib in combination with Opdivo
Non-small cell lung cancer